Moiseev S. Bossuyt X. Arimura Y. et al.

International Consensus on Antineutrophil Cytoplasmic Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis.

Am J Respir Crit Care Med. 202: 1360-1372Nada A.K. Torres V.E. Ryu J.H. et al.

Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients.

Mayo Clin Proc. 65: 847-856Arimura Y. Minoshima S. Tanaka U. et al.

Pulmonary involvement in patients with myeloperoxidase specific-antineutrophil cytoplasmic antibody.

Ryumachi. 35: 46-55Alba M.A. Flores-Suárez L.F. Henderson A.G. et al.

Interstitial lung disease in ANCA vasculitis.

Autoimmun Rev. 16: 722-729Hozumi H. Enomoto N. Oyama Y. et al.

Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias.

Lung. 194: 235-242Tzelepis G.E. Kokosi M. Tzioufas A. et al.

Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis.

Eur Respir J. 36: 116-121Ando M. Miyazaki E. Ishii T. et al.

Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangiitis in the course of idiopathic pulmonary fibrosis.

Respir Med. 107: 608-615Liu G.Y. Ventura I.B. Achtar-Zadeh N. et al.

Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in North American patients with idiopathic pulmonary fibrosis.

Chest. 156: 715-723Kagiyama N. Takayanagi N. Kanauchi T. et al.

Anti-neutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis.

BMJ Open Respir Res. 2: e000058Sun X. Peng M. Zhang T. et al.

Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody.

BMC Pulm Med. 21: 88Lyons P.A. Rayner T.F. Trivedi S. et al.

Genetically distinct subsets within ANCA-associated vasculitis.

N Engl J Med. 367: 214-223McDermott G. Fu X. Stone J.H. et al.

Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

JAMA Intern Med. 180: 870-876Kitching A.R. Anders HJ. Basu N. et al.

ANCA-associated vasculitis.

Nat Rev Dis Primers. 6: 71https://doi.org/10.1038/s41572-020-0204-yLane S.E. Watts R.A. Bentham G. et al.

Are environmental factors important in primary systemic vasculitis? A case-control study.

Arthritis Rheum. 48: 814-823Fujimoto S. Watts R.A. Kobayashi S. et al.

Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K.

Rheumatology. 50: 1916-1920Sada K.E. Harigai M. Amano K. et al.

Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study.

Mod Rheumatol. 26: 730-737Berti A. Cornec D. Crowson C.S.

The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study.

Arthritis Rheum. 69: 2338-2350Mohammad A.J. Jacobsson L.T. Mahr A.D. et al.

Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden.

Rheumatology. 46: 1329-1337Seibold M.A. Wise A.L. Speer M.C. et al.

A common MUC5B promoter polymorphism and pulmonary fibrosis.

N Engl J Med. 364: 1503-1512Stock C.J. Sato H. Fonseca C. et al.

Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis.

Thorax. 68: 436-441Yang I.V. Fingerlin T.E. Evans C.M. et al.

MUC5B and Idiopathic Pulmonary Fibrosis.

Ann Am Thorac Soc. 12: S193-S199Namba N. Kawasaki A. Sada K. et al.Ann Rheum Dis. 78: 1144-1146Foucher P. Heeringa P. Petersen A.H. et al.

Antimyeloperoxidase-associated lung disease. An experimental model.

Am J Respir Crit Care Med. 160: 987-994Guilpain P. Chereau C. Goulvestre C. et al.

The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis.

Eur Respir J. 37: 1503-1513Metzler K.D. Fuchs T.A. Nauseef W.M. et al.

Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity.

Blood. 117: 953-959Thiam H.R. Wong S.L. Wagner D.D. et al.

Cellular Mechanisms of NETosis.

Annu Rev Cell Dev Biol. 36: 191-218Chrysanthopoulou A. Mitroulis I. Apostolidou E. et al.

Neutrophil extracellular traps promote differentiation and function of fibroblasts.

J Pathol. 233: 294-307Lee K.Y. Ho S.C. Lin H.C. et al.

Neutrophil-derived elastase induces TGF-beta1 secretion in human airway smooth muscle via NF-kappaB pathway.

Am J Respir Cell Mol Biol. 35: 407-414

NET balancing: a problem in inflammatory lung diseases.

Front Immunol. 4: 1

Rare diseases bullet 10: Small vessel vasculitis of the lung.

Thorax. 55: 502-510

Pulmonary capillaritis.

Semin Respir Crit Care Med. 25: 547-555Schwarz M.I. Zamora M.R. Hodges T.N. et al.

Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease.

Chest. 113: 1609-1615

Alveolar Hemorrhage in Vasculitis (Primary and Secondary).

Semin Respir Crit Care Med. 39: 482-493Gallagher H. Kwan J.T. Jayne D.R.

Pulmonary renal syndrome: a 4-year, single-center experience.

Am J Kidney Dis. 39: 42-47

Idiopathic pulmonary hemosiderosis: A state of the art review.

Respir Med. 176: 106234Magro C.M. Allen J. Pope-Harman A. et al.

The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis.

Am J Clin Pathol. 119: 556-567Arulkumaran N. Periselneris N. Gaskin G. et al.

Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study.

Rheumatology. 50: 2035-2043Ando Y. Okada F. Matsumoto S. et al.

Thoracic manifestation of myeloperoxidase/antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients.

J Comput Assist Tomogr. 28: 710-716Suarez-Cuartin G. Molina-Molina M.

Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients.

Breathe. 16: 190321Baqir M. Yi E.E. Colby T.V. et al.

Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis.

Sarcoidosis Vasc Diffuse Lung Dis. 36: 195-201Kwon M. Lee A.S. Mira-Avendano I. et al.

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients: Comparison With Idiopathic Pulmonary Fibrosis.

J Clin Rheumatol. 27: 324-330Huang H. Wang Y.X. Jiang C.G. et al.

A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China.

BMC Pulm Med. 14: 8Tzouvelekis A. Zacharis G. Oikonomou A. et al.

Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis.

Eur Respir J. 40: 505-507Gocho K. Sugino K. Sato K. et al.

Microscopic polyangiitis preceded by combined pulmonary fibrosis and emphysema.

Respir Med Case Rep. 15: 128-132Raghu G. Remy-Jardin M. Richeldi L. et al.

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Am J Respir Crit Care Med. 205: e18-e47Watanabe T. Minezawa T. Hasegawa M. et al.

Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study.

BMC Pulm Med. 19: 194Wurmann P. Sabugo F. Elgueta F. et al.

Interstitial lung disease and microscopic polyangiitis in Chilean patients.

Sarcoidosis Vasc Diffuse Lung Dis. 37: 37-42Suzuki A. Sakamoto S. Kurosaki A. et al.

Chest High-Resolution CT Findings of Microscopic Polyangiitis: A Japanese First Nationwide Prospective Cohort Study.

AJR Am J Roentgenol. 213: 104-114Yamagata M. Ikeda K. Tsushima K. et al.

Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients.

Arthritis Rheumatol. 68: 713-723Doliner B. Rodriguez K. Montesi S.B. et al.

Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features, and mortality.

Rheumatology. keac339 ()Comarmond C. Crestani B. Tazi A. et al.

Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature.

Medicine (Baltim). 93 (): 340-349Imokawa S. Uehara M. Uto T. et al.

Organizing pneumonia associated with myeloperoxidase anti-neutrophil cytoplasmic antibody.

Respirol Case Rep. 3: 122-124Takada K. Miyamoto A. Nakahama H. et al.

Myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis with a unique imaging presentation of organizing pneumonia: A case report.

Respir Med Case Rep. 31: 101294Yates M. Watts R.A. Bajema I.M. et al.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the.

Rheumatic Diseases. 75: 1583-1594Hervier B. Pagnoux C. Agard C. et al.

Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature.

Ann Rheum Dis. 68: 404-407Yamaguchi K. Yamaguchi A. Itai M. et al.

Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients.

Rheumatol Int. 41: 1641-1650Kawamura K. Ichikado K. Ichiyasu H. et al.

Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience.

BMC Pulm Med. 19: 113Idiopathic Pulmonary Fibrosis Clinical Research Network Raghu G. Anstrom K.J. et al.

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

N Engl J Med. 366: 1968-1977

New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern?.

Curr Opin Pulm Med. 25: 442-449Wells A.U. Flaherty K.R. Brown K.K. et al.

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

Lancet Respir Med. 8: 453-460Behr J. Prasse A. Kreuter M. et al.

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.

Lancet Respir Med. 9: 476-486

Current perspective of progressive-fibrosing interstitial lung disease.

Respir Investig. 60: 503-509Adegunsoye A. Oldham J.M. Bellam S.K. et al.

Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases.

Ann Am Thorac Soc. 16: 580-588Yamakawa H. Toyoda Y. Baba T. et al.

Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.

J Clin Med. 11: 3835

Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis.

Chron Respir Dis. 18 ()Hozumi H. Kono M. Hasegawa H. et al.

Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis.

Chest. 159: 2334-2345